OncoRes Medical Secures AUD $27M. Advances Precision in Breast Cancer Surgery with Elora System.
February 21, 2026, 4:07 pm
OncoRes Medical raised AUD $27M in private funding. This propels development of its Elora system. Elora provides real-time intraoperative imaging. It targets residual tumor detection in breast cancer surgery. The device aims to dramatically reduce repeat operations. Funds support ongoing clinical trials, critical regulatory milestones, and strategic U.S. market entry. This innovation promises enhanced surgical precision and profoundly improved patient outcomes.
OncoRes Medical, an Australian innovator, recently secured AUD $27 million. This significant private funding round accelerates the development of its groundbreaking Elora system. The Perth-based medical device company is poised for a major impact. Its focus remains on transforming breast cancer surgery.
Breast-conserving surgery is a vital treatment. Yet, a significant challenge persists. Many patients require repeat operations. Incomplete tumor removal often necessitates these follow-up procedures. This imposes substantial burdens. Patients face increased risks. They endure psychological, physical, and financial strains. The healthcare system also absorbs considerable costs. Elora addresses this critical unmet need directly.
The Elora system is a quantitative micro-elastography (QME) imaging device. It offers real-time tumor assessment. Surgeons gain immediate insight during operations. A probe is inserted into the surgical cavity. This happens after the main specimen's excision. The device generates detailed, three-dimensional maps. These maps highlight the mechanical and optical properties of scanned tissue. Cancerous tissue often exhibits different stiffness. Elora leverages this distinction. It identifies microscopic residual cancer. This enhances a surgeon's ability to ensure complete removal.
This advanced technology holds immense promise. It offers surgeons newfound confidence. They can identify and remove cancerous tissue more precisely. The goal is clear: leave no residual cancer behind. This direct feedback during surgery is a game-changer. It minimizes uncertainty. It maximizes the chance of a successful primary operation.
The recent AUD $27 million capital injection fuels key initiatives. It supports ongoing Australian clinical trials. It advances product development. Critical regulatory work is a major focus. The company prepares for manufacturing ahead of a U.S. pivotal trial. Team expansion also receives support. Early proof-of-concept work in additional cancer indications is planned. Prostate cancer is a prime candidate for future exploration.
Investor confidence in OncoRes Medical is strong. The funding round saw participation from major entities. Brandon Capital Partners’ BB6 Fund provided a cornerstone investment. Significant contributions came from Morgans and Radar Ventures. Australian and international family offices also invested. The Table Club network joined the round. This diverse backing underscores the technology's potential.
OncoRes Medical has already initiated its Australian clinical trial. This trial spans six hospitals. It operates across two Australian states: Western Australia and Victoria. Over 110 breast cancer patients will participate. This trial marks a pivotal moment. It is the first time the Elora device will be used interventionally. This direct clinical application provides crucial data. It validates Elora's efficacy in real-world surgical settings.
The company's strategic path includes aggressive U.S. market entry. Elora received FDA Breakthrough Device Designation in 2020. This status is vital. It supports the timely development of promising medical technologies. These technologies must offer more effective treatment. They target life-threatening or irreversibly debilitating conditions. The designation accelerates the regulatory pathway. It can expedite access and reimbursement after FDA approval. This fast-tracks Elora's availability to U.S. patients.
Strategic leadership strengthens OncoRes Medical's journey. Renee Ryan has joined the company's board. Ryan brings decades of experience. She is a global leader in healthcare and medical devices. Her expertise spans strategic innovation and capital raising. Executive-level leadership defines her career. Her presence signals a focused drive toward commercial success. She currently co-founds and leads PinPrint.
The innovation behind Elora stems from significant research. Technology originates from the University of Western Australia. The Harry Perkins Institute also contributed. The Western Australian Department of Health played a role. This collaboration highlights a robust scientific foundation. It reflects a commitment to advanced medical solutions.
Elora represents a significant leap forward. It addresses a core problem in surgical oncology. Reducing repeat surgeries provides immense relief. Patients avoid additional trauma and stress. Healthcare systems gain efficiency. The prospect of one successful surgery vastly improves quality of life. This technology empowers surgeons. It offers them a powerful tool. They can achieve cleaner margins. They can ensure better long-term outcomes for patients.
The journey continues for OncoRes Medical. Elora remains in research and development. It is not yet available for sale worldwide. But its trajectory is clear. The company aims for regulatory approval. A U.S. commercial ramp-up is in sight. Expanding this innovative, patient-centric technology is the ultimate goal. From Australia to the U.S. and beyond, Elora seeks to redefine breast cancer surgery. It promises a future where fewer patients return to the operating room. This translates to profound improvements in global cancer care. The impact on countless lives will be immense.
OncoRes Medical, an Australian innovator, recently secured AUD $27 million. This significant private funding round accelerates the development of its groundbreaking Elora system. The Perth-based medical device company is poised for a major impact. Its focus remains on transforming breast cancer surgery.
Breast-conserving surgery is a vital treatment. Yet, a significant challenge persists. Many patients require repeat operations. Incomplete tumor removal often necessitates these follow-up procedures. This imposes substantial burdens. Patients face increased risks. They endure psychological, physical, and financial strains. The healthcare system also absorbs considerable costs. Elora addresses this critical unmet need directly.
The Elora system is a quantitative micro-elastography (QME) imaging device. It offers real-time tumor assessment. Surgeons gain immediate insight during operations. A probe is inserted into the surgical cavity. This happens after the main specimen's excision. The device generates detailed, three-dimensional maps. These maps highlight the mechanical and optical properties of scanned tissue. Cancerous tissue often exhibits different stiffness. Elora leverages this distinction. It identifies microscopic residual cancer. This enhances a surgeon's ability to ensure complete removal.
This advanced technology holds immense promise. It offers surgeons newfound confidence. They can identify and remove cancerous tissue more precisely. The goal is clear: leave no residual cancer behind. This direct feedback during surgery is a game-changer. It minimizes uncertainty. It maximizes the chance of a successful primary operation.
The recent AUD $27 million capital injection fuels key initiatives. It supports ongoing Australian clinical trials. It advances product development. Critical regulatory work is a major focus. The company prepares for manufacturing ahead of a U.S. pivotal trial. Team expansion also receives support. Early proof-of-concept work in additional cancer indications is planned. Prostate cancer is a prime candidate for future exploration.
Investor confidence in OncoRes Medical is strong. The funding round saw participation from major entities. Brandon Capital Partners’ BB6 Fund provided a cornerstone investment. Significant contributions came from Morgans and Radar Ventures. Australian and international family offices also invested. The Table Club network joined the round. This diverse backing underscores the technology's potential.
OncoRes Medical has already initiated its Australian clinical trial. This trial spans six hospitals. It operates across two Australian states: Western Australia and Victoria. Over 110 breast cancer patients will participate. This trial marks a pivotal moment. It is the first time the Elora device will be used interventionally. This direct clinical application provides crucial data. It validates Elora's efficacy in real-world surgical settings.
The company's strategic path includes aggressive U.S. market entry. Elora received FDA Breakthrough Device Designation in 2020. This status is vital. It supports the timely development of promising medical technologies. These technologies must offer more effective treatment. They target life-threatening or irreversibly debilitating conditions. The designation accelerates the regulatory pathway. It can expedite access and reimbursement after FDA approval. This fast-tracks Elora's availability to U.S. patients.
Strategic leadership strengthens OncoRes Medical's journey. Renee Ryan has joined the company's board. Ryan brings decades of experience. She is a global leader in healthcare and medical devices. Her expertise spans strategic innovation and capital raising. Executive-level leadership defines her career. Her presence signals a focused drive toward commercial success. She currently co-founds and leads PinPrint.
The innovation behind Elora stems from significant research. Technology originates from the University of Western Australia. The Harry Perkins Institute also contributed. The Western Australian Department of Health played a role. This collaboration highlights a robust scientific foundation. It reflects a commitment to advanced medical solutions.
Elora represents a significant leap forward. It addresses a core problem in surgical oncology. Reducing repeat surgeries provides immense relief. Patients avoid additional trauma and stress. Healthcare systems gain efficiency. The prospect of one successful surgery vastly improves quality of life. This technology empowers surgeons. It offers them a powerful tool. They can achieve cleaner margins. They can ensure better long-term outcomes for patients.
The journey continues for OncoRes Medical. Elora remains in research and development. It is not yet available for sale worldwide. But its trajectory is clear. The company aims for regulatory approval. A U.S. commercial ramp-up is in sight. Expanding this innovative, patient-centric technology is the ultimate goal. From Australia to the U.S. and beyond, Elora seeks to redefine breast cancer surgery. It promises a future where fewer patients return to the operating room. This translates to profound improvements in global cancer care. The impact on countless lives will be immense.